Abstract: The invention provides compositions and methods for treatment of proliferative vitreoretinopathy.

Abstract: The invention provides compositions and methods for treatment of proliferative vitreoretinopathy.

Abstract: The invention provides compositions and methods for treatment of proliferative vitreoretinopathy.

Abstract: The invention provides compositions and methods for treatment of proliferative vitreoretinopathy.

Abstract: The invention provides compositions and methods for treatment of proliferative vitreoretinopathy.

Abstract: The invention provides methods and compositions for identifying and quantifying pathological changes on the retina.

Abstract: The invention provides methods and compositions for identifying and quantifying pathological changes on the retina.

Abstract: The present invention provides a method of determining the disease state of a disease or condition associated with EC dysfunction in a subject. An exemplary method screens for elevated profilin-1 levels as a marker for DVD and other vascular diseases such as atherosclerosis, cerebrovascular disease, CVD or peripheral vascular disease. The invention also provides a method for the prophylaxis or treatment of such diseases or conditions associated with EC dysfunction. The method comprises administering to a subject a therapeutic composition or carrying out a protocol to inhibit the activity or function of profilin-1. In an embodiment, the composition comprises an inhibitor of profilin-1 activity or function administered in a pharmaceutically acceptable carrier. The therapeutic protocol or method can, for instance, be siRNA based or a strategy for gene therapy. The invention further provides a kit that can be used to carry out a diagnostic method.

Abstract: The invention provides methods and compositions for treating diseases and conditions, which are associated with an abnormal PDGF level or response, such as cell proliferation, cell migration, extracellular matrix synthesis and secretion, and cell contraction. Exemplary diseases or disorders include cell proliferative diseases and fibrotic diseases. Exemplary fibrotic diseases include those resulting from a wound healing process, such as excessive scarring and PVR. Generally, the method comprise administering to a subject in need thereof a pharmaceutically efficient amount of a nucleic acid encoding a mutated PDGFR. The invention further provides gel contraction assays for identifying compounds for treating or preventing the development of diseases involving cell contraction, e.g., fibrotic diseases.

Abstract: The invention provides methods and compositions for treating diseases and conditions, which are associated with an abnormal PDGF level or response, such as cell proliferation, cell migration, extracellular matrix synthesis and secretion, and cell contraction. Exemplary diseases or disorders include cell proliferative diseases and fibrotic diseases. Exemplary fibrotic diseases include those resulting from a wound healing process, such as excessive scarring and PVR. Generally, the method comprise administering to a subject in need thereof a pharmaceutically efficient amount of a nucleic acid encoding a mutated PDGFR. The invention further provides gel contraction assays for identifying compounds for treating or preventing the development of diseases involving cell contraction, e.g., fibrotic diseases.